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The frequency of respiratory tract infections caused by Ralstonia species in persons with cystic fibrosis
(CF) and the role of these species in CF pulmonary disease are not well documented. In part, this lack of
documentation may be attributed to the difficulty in accurately identifying Ralstonia species; R. mannitoli-
lytica and R. pickettii in particular may be misidentified as other closely related species, particularly those
of the Burkholderia cepacia complex.  We used polyphasic analyses to identify 42 Ralstonia isolates from
sputum cultures from 38 CF patients. Several isolates that could not be identified to the species level may
belong to novel Ralstonia species. We demonstrated chronic colonization by using genotyping of serial
isolates recovered from the same patient. To facilitate identification of R. mannitolilytica and R. pickettii, we
developed 16S ribosomal DNA-based polymerase chain reaction assays that allow sensitive and specific
identification of these species.
ystic fibrosis (CF) is the most frequent hereditary disease
in Caucasian populations (1); chronic microbial coloni-
zation of the large airways, leading to exacerbations of pulmo-
nary infection, is the major cause of illness and death in CF
patients. Typical CF pathogens include Staphylococcus aureus,
Pseudomonas aeruginosa,  Haemophilus influenzae, and
Burkholderia cepacia complex; other species, including
Stenotrophomonas maltophilia, Alcaligenes (Achromobacter)
xylosoxidans, B. gladioli, and R. pickettii have been recovered
from sputum cultures of CF patients as well (2,3). Recently,
we showed that a number of unusual bacterial species (includ-
ing several novel species within the α -Proteobacteria) are also
occasionally isolated from CF patients (4). Infection with
mucoid P. aeruginosa and members of the B. cepacia complex
is associated with increased illness and death in CF patients
(5–7), but the clinical importance of infection with these other
species is less clear. 
The genus Ralstonia was proposed in 1995 (8). Since its
creation, the taxonomy of the genus has expanded to include
11 species, which are R. pickettii, R. solanacearum, R. eutro-
pha,  R. gilardii,  R. paucula,  R. basilensis, R. oxalatica,  R.
mannitolilytica, R. taiwanensis, R. campinensis, and R. metal-
lidurans (8–14). Ralstonia spp. are isolated from a wide vari-
ety of ecologic niches, including plants and soils contaminated
with heavy metals. R. pickettii has been associated with noso-
comial outbreaks caused by contaminated solutions used for
patient care and with pseudoepidemics caused by contami-
nated solutions in the diagnostic laboratory (15–21). Several
hospital-associated outbreaks attributed to R. mannitolilytica
(formerly known as R. pickettii biovar 3 or P. thomasii) have
been described (12,22,23). R. paucula and  R. gilardii have
only sporadically been isolated from human clinical samples,
including cerebrospinal fluid, bone marrow, wounds, and the
respiratory tract (9,10). A complete assessment of the fre-
quency of human infection due to Ralstonia species is con-
founded by the difficulty in accurate species identification by
using standard microbiologic techniques. Indeed, these species
are frequently misidentified as P. fluorescens or B. cepacia
complex (12,24–26).
We describe the occurrence of several Ralstonia species in
the respiratory secretions of CF patients. We also describe the
development and evaluation of two polymerase chain reaction
(PCR) assays for rapid, accurate identification of R. pickettii
and R. mannitolilytica.
Materials and Methods
Bacterial Strains and Study Population
Since early 1997, the Burkholderia cepacia Research Lab-
oratory and Repository (University of Michigan, Ann Arbor,
MI) has received more than 4,000 bacterial isolates, collected
from CF patients receiving care in 145 CF treatment centers in
130 U. S. cities. Isolates received were tentatively identified
by the referring microbiology laboratory as B. cepacia com-
plex or a related species or were not identified to the species
level. From these isolates, we identified 42 Ralstonia isolates
obtained from 38 patients who had received care in 19 treat-
ment centers in 18 U. S. cities. The type and reference strains
of  Ralstonia,  Pandoraea,  Burkholderia,  Alcaligenes,  and
Bordetella species have been described (9–14). These strains
were obtained from the BCCM/LMG-Bacteria Collection
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(Laboratorium voor Microbiologie, Universiteit Gent, Bel-
gium) or were provided by D. Henry (University of British
Columbia, Vancouver, Canada). All isolates were grown aero-
bically on Mueller-Hinton broth (Becton, Dickinson and Com-
pany, Cockeysville, MD) supplemented with 1.8% (wt/vol)
agar and incubated at 32°C.
Species Identification
We used a polyphasic approach to identify all isolates,
including biochemical tests, 16S ribosomal (r)DNA-based
PCR assays and sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) of whole-cell proteins. Biochem-
ical tests (determination of oxidase, lysine decarboxylase, and
o-nitrophenyl-β -D-galactoside activity; growth on B. cepacia
selective agar; and oxidation-fermentation of sucrose) were
performed as described (27). SDS-PAGE of whole-cell pro-
teins was performed as described (9,10), and isolates were
identified by comparison with a database containing protein
profiles of all Ralstonia species. We used 16S rDNA-based
PCR assays (28) to determine whether or not isolates belonged
to the genera Burkholderia or Ralstonia or to the B. cepacia
complex.
Genotyping of Serial Isolate
Multiple isolates from a single patient were genotyped by
randomly amplified polymorphic DNA (RAPD) genotyping as
described (29). We digitized gel images with a GelDoc2000
gel analyzer (Bio-Rad Laboratories, Hercules, CA) and stored
them as tagged image files. After normalization with the
molecular weight marker, patterns were analyzed with Molec-
ular Analyst Fingerprinting Plus software (Bio-Rad Laborato-
ries). Similarities between patterns were calculated by using
Pearson’s product-moment correlation coefficient. We consid-
ered isolates to belong to the same genotype if they shared
90% or more similarity. 
Development of Primers for Species-Specific PCR Assays
We retrieved 16S rDNA sequences of all Ralstonia spp.
and representatives of related genera from the GenBank data-
base, using the MegAlign software package (DNASTAR Inc.,
Madison, WI) to align the sequences. Based on this alignment,
we developed primers specific for R. pickettii and R. mannito-
lilytica: Rp-F1 (5´-ATGATCTAGCTTGCTAGATTGAT-3´)
and Rp-R1 (5´-ACTGATCGTCGCCTTGGTG-3´) (forward
and reverse primers for the identification of R. pickettii) and
Rm-F1 (5´-GGGAAAGCTTGCTTTCCTGCC-3´) and Rm-
R1 (5´-TCCGGGTATTAACCAGAGCCAT-3´) (forward and
reverse primers for the identification of R. mannitolilytica). 
Polymerase Chain Reaction
DNA was prepared as described (30). PCR assays were
performed in 25-µL reaction mixtures, containing 2 µL DNA
solution, 1U Taq polymerase (GIBCO Invitrogen Corp., Gaith-
ersburg, MD), 250 mM (each) deoxynucleotide triphosphate
(GIBCO Invitrogen Corp.), 1.5 mM MgCl2, 1x PCR buffer
(GIBCO Invitrogen Corp.), and 20 pmol of each oligonucle-
otide primer. Amplification was carried out with a PTC-100
programmable thermal cycler (Labtrade Inc., Miami, FL).
After initial denaturation for 2 min at 94°C, 30 amplification
cycles were completed, each consisting of 1 min at 94°C, 1
min at 55°C (for identifying R. pickettii) or 57°C (for identify-
ing R. mannitolilytica), and 1 min 30 s at 72°C. A final exten-
sion of 10 min at 72°C was applied. Negative control PCRs
with all reaction mixture components except template DNA
were used for every experiment.
Evaluation of the PCR Assays
For evaluating PCR assays, we tested 152 isolates, includ-
ing 79 Ralstonia isolates (both clinical isolates and reference
strains) and 73 isolates representing phylogenetically related
species that may be found in sputum cultures of CF patients.
Isolates tested were as follows: R. pickettii (27 isolates), R.
mannitolilytica (34), R. gilardii (4), R. paucula (2), R. taiwan-
ensis (1), R. basilensis (1), R. eutropha (1), R. oxalatica (1), R.
solanacearum (1), R. campinensis (1), R. metallidurans (1),
Ralstonia sp. (5), B. cepacia genomovar I (3), B.  multivorans
(2), B. cepacia genomovar III (7), B. stabilis (2), B. vietnam-
iensis (2), B. cepacia genomovar VI (5), B. ambifaria (3), B.
gladioli (6), B. fungorum (1), Pandoraea apista (5), P. norim-
bergensis (3), P. pnomenusa (2), P.  sputorum (4), P. pulmoni-
cola (2), Alcaligenes xylosoxidans (5), P. aeruginosa (5), S.
maltophilia (5), and one isolate each of A. denitrificans, A.
piechaudii, A. faecalis, A. ruhlandii, Bordetella avium, B. hin-
zii, B. trematum, B. bronchiseptica, B. pertussis, B. paraper-
tussis, and B. holmesii. 
Results
Species Identification
Isolates were tentatively identified as belonging to the
genus Ralstonia if they 1) reacted with primer pair RHG-F/
RHG-R (specific for Burkholderia and Ralstonia spp.) (28), 2)
showed no lysine decarboxylase and o-nitrophenyl-β -D-galac-
toside activity, 3) produced no acid from sucrose, and 4)
showed oxidase activity. Using these criteria, we identified 42
putative  Ralstonia  sp. isolates. These isolates were further
identified to the species level by using SDS-PAGE of whole-
cell proteins. Most isolates (25) were identified as R. mannito-
lilytica; 9 were identified as R. pickettii. Two isolates were
identified as R. gilardii, and another as R. taiwanensis. Five
isolates clearly belonged to the genus Ralstonia but could not
be classified into one of the known species. Pending further
investigations, these isolates were classified as Ralstonia sp.
Genotyping of Serial Isolates
We identified two patients (A and B) who were sputum-
culture positive for R. mannitolilytica and one patient (C) who
was culture positive for R. pickettii on more than one occasion.
The three R. mannitolilytica isolates cultured from patient A
were recovered over a period of >2 years. RAPD genotypingRESEARCH
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indicated that the first isolate clearly differed from the two iso-
lates recovered subsequently; the latter two isolates (recovered
20 months apart) were the same genotype (Figure 1). Simi-
larly, the two R. mannitolilytica isolates recovered from
patient B (cultured 8 weeks apart) were the same genotype, as
were the two R. pickettii isolates recovered from patient C
(cultured 6 weeks apart) (Figure 1).
Primer Design
Alignment of 16S rRNA gene sequences of Ralstonia sp.
available in GenBank showed similarity values >93.1% and
>98.2% within the species R. pickettii and R. mannitolilytica,
respectively. Identity of sequences between these two species
ranged from 89.9% to 96.8%. Several species-level sequence
signatures were detected and were incorporated into the spe-
cies-specific primers Rp-F1 and Rp-R1 (forward and reverse
primer for R. pickettii) and Rm-F1 and Rm-R1 (forward and
reverse primer for R. mannitolilytica). PCR with these primers
resulted in the amplification of fragments of 210 bp and 398
bp, respectively (Figure 2). Each of the 152 strains included in
this study was examined by PCR with the primer pairs
described (Table). 
Discussion
The occurrence and clinical role of Ralstonia sp. in the res-
piratory secretions of persons with CF have not been systemat-
ically investigated because of the rapidly changing taxonomy
of the genus Ralstonia and the absence of rapid, reliable meth-
ods for species identification. We used a polyphasic approach
to identify Ralstonia sp. in sputum cultures of CF patients and
developed two PCR assays for identifying R. pickettii and R.
mannitolilytica.
Previous reports describing the bacterial flora of the respi-
ratory tract of CF patients have focused mainly on P. aerugi-
nosa and B. cepacia complex organisms (3,5,31); reports
describing the presence of Ralstonia species in sputum cul-
tures of CF patients are scarce and often anecdotal. In a pro-
spective study, Burns et al. (2) isolated R. pickettii from only 2
of 559 patients. More recently, we have shown that other Ral-
stonia  species, including R. mannitolilytica,  R. taiwanensis,
and R. gilardii, can also be isolated from the respiratory secre-
tions of CF patients (4). In this study, we identified Ralstonia
species recovered from sputum cultures of 38 CF patients.
Collectively, these data indicate that the prevalence of Ralsto-
nia sp. in the CF population is rather low. However, because
we did not specifically survey all referring laboratories for all
Ralstonia species that may have been recovered from CF spec-
imens, we were not able to define a more precise prevalence of
Ralstonia sp. in the CF population. 
Our data do not provide evidence for patient-to-patient
spread of Ralstonia sp. because no clustering of cases occurred
within centers or geographic regions (data not shown). How-
ever, we were able to document persistent colonization with
Ralstonia species in three patients. Patient A’s infection is par-
ticularly interesting. In this patient, an initial R. mannitolily-
tica strain was apparently replaced with another strain, which
then persisted for >20 months. However, the bacterial and host
factors involved in infection by more than one R. mannitolilyt-
ica strain or with chronic colonization remain to be defined. 
Five Ralstonia isolates could not be identified to the spe-
cies level. 16S rDNA PCR and SDS-PAGE of whole-cell pro-
teins clearly indicated that these isolates belong to the genus
Ralstonia, suggesting that they may represent novel Ralstonia
sp. Further polyphasic taxonomic studies are needed to clarify
their status. The finding of R. mannitolilytica, R. gilardii, R.
taiwanensis, and possible novel Ralstonia species in respira-
tory secretions of CF patients suggests that these organisms
may be emerging human pathogens and again highlights the
fact that the bacterial biodiversity in the respiratory tract of CF
patients has thus far been underestimated (4).
Of the 25 R. mannitolilytica strains identified in this study,
9 were initially identified by the referring laboratory as R.
pickettii, 8 as B. cepacia complex, 6 as Burkholderia sp., 1 as
B. gladioli, and 1 as P. fluorescens. Of the 9 R. pickettii strains
identified, 3 were identified by the referring laboratory as R.
pickettii, 2 as Burkholderia sp., 1 as Pseudomonas sp., 1 as B.
cepacia complex, and 2 isolates as unidentified. The R. gilar-
dii and R. taiwanensis isolates were received as B. cepacia
complex and S. maltophilia, respectively. Most (81%) of these
isolates were capable of growth on B. cepacia selective agar.
These observations reiterate that identification of these species
is not straightforward and that their misidentification as other
CF pathogens, such as B. cepacia complex, is not uncommon.
Such misidentification has an important impact on infection
control in CF since the efficiency of these measures depends
on accurate identification of the microorganisms involved.
Infection-control policies, particularly those recommended to
prevent interpatient spread of B. cepacia complex, have a tre-
mendous impact on the quality of life of CF patients (6,7). To
enhance accurate identification of CF pathogens, several PCR
assays have been developed recently (28,30,32–35). We
Figure 1. Randomly amplified polymorphic DNA analysis of serial iso-
lates from three patients. M: molecular weight marker; lanes 1, 2, and
3: serial Ralstonia mannitolilytica isolates from patient A in chronologi-
cal order; lanes 4 and 5: serial R. mannitolilytica isolates from patient B
in chronological order; and lanes 6 and 7: serial R. pickettii isolates
from patient C in chronological order.Emerging Infectious Diseases  •  Vol. 8, No. 7, July 2002 695
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sought to design similar PCR tests to allow the identification
of R. pickettii and R. mannitolilytica based on species-level
signature sequences in the 16S rRNA gene. By comparing
available R. pickettii and R. mannitolilytica 16S rRNA gene
sequences with sequences from other Ralstonia species and
representatives of the phylogenetically closely related genera
Burkholderia  and  Pandoraea, we identified several regions
that showed sufficient diversity to allow the design of primer
pairs Rp-F1/Rp-R1 and Rm-F1/Rm-R1, permitting the sensi-
tive and specific identification of R. pickettii and R. mannitoli-
lytica, respectively (Table). 
The results of our study indicate that a number of Ralsto-
nia  species can be isolated from sputum cultures of CF
patients. The correct identification of these species presents a
challenge for diagnostic microbiology laboratories. Our study
supports the use of genotypic methods to augment routine phe-
notypic evaluation. The combined use of the two PCR assays
described will allow the identification of most Ralstonia spe-
cies encountered in sputum cultures of CF patients. Most
importantly, the use of these assays will substantially reduce
the misidentification of R. pickettii and R. mannitolilytica as B.
cepacia complex. These tests will be a valuable adjunct in the
evaluation of CF sputum culture isolates and will allow more
precise study of the prevalence and natural history of human
infection by these emerging pathogens.
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